Cite
HARVARD Citation
D'Amico, L. et al. (2019). A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. Journal for immunotherapy of cancer. 7 (1), p. . [Online].